REG - FTSE Russell AstraZeneca PLC - AstraZeneca
RNS Number : 4287FFTSE Russell15 July 2021
O
AstraZeneca (UK): Acquisition of Alexion Pharmaceuticals (USA)
Changes in FTSE UK Index Series15 July 2021
Subject to the completion of the cash and stock acquistion of Alexion Pharmaceuticals (USA, non-constituent) by AstraZeneca (UK, constituent), please see details of affected indexes and effective dates below:
Index
Effective From
Start of TradingFTSE 100 Index
21 July 2021
FTSE 350 Index
21 July 2021
FTSE All-Share Index
21 July 2021
FTSE 350 Higher Yield Index
21 July 2021
Techmark All Share Index
21 July 2021
For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:
Australia
+1800 653 680
Hong Kong
+852 2164 3333
Japan
+81 3 4563 6346
London
+44 (0) 20 7866 1810
New York
+1866 551 0617
Alternatively please visit our website at www.ftserussell.com
Terms of Use | Copyright © 2021 FTSE Russell
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDFTSSFFFMIEFSEFW
Recent news on AstraZeneca
See all newsREG - AstraZeneca PLC - 1st Quarter Results
AnnouncementREG - Stock Exch Notice - Admission to ISM - 17/04/2024
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - AstraZeneca increases 2024 dividend by 7%
AnnouncementREG - AstraZeneca PLC - Enhertu approved in US for HER2+ solid tumours
Announcement